Skip to main content
. Author manuscript; available in PMC: 2022 Jan 1.
Published in final edited form as: Cancer Res. 2021 Apr 28;81(13):3580–3592. doi: 10.1158/0008-5472.CAN-20-2773

Figure 3: The EGFRvIII mutation causes EGF-independent TAZ hyperactivation in GBM cells.

Figure 3:

A: EGFR western blotting using total protein lysates from GBM cells. 293FT cells with lentiviral EGFRvIII expression were used as the positive control.

B and C: GBM1B and U87MG cells with +/− EGFRvIII expression were subjected to TAZ western blotting (B). GBM1B cells with +/− EGFRvIII expression were subjected to qRT-PCR for two TAZ gene targets (C).

D: GBM cells as marked were depleted of growth factors for 16 hours and treated with EGF for the indicated times (Con: EGF-untreated cells). Total protein lysates were subjected to western blotting of TAZ and EGFR-activated kinases.

Protein fold expression normalized to β-Actin, total ERK1/2 or STAT3 is shown below each lane. Data are represented as mean ± SEM (*: p<0.01).